Lung cancer is one of the most common malignant tumors with the highest incidence. Gene mutations are rare in small-cell lung carcinoma (SCLC), resulting in targeted therapy being only a third-line recommendation. Surufatinib (Sulanda) is an oral angio-immune kinase inhibitor used to treat solid tumors. We report a case of SCLC treated with surufatinib combined with camrelizumab, with good therapeutic results in our department. The patient experienced over 18 months of progression-free survival and over 28 months of overall survival. This suggests that surufatinib combined with camrelizumab is an effective third-line treatment for SCLC patients. However, the response rate to surufatinib treatment in all patients with SCLC remains unknown and needs to be determined in a large population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.
Front Pharmacol
November 2024
Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Introduction: Gemcitabine and cisplatin remain the cornerstone for the treatment of advanced or unresectable biliary tract cancers, but the incidence rate of the grade 3 or 4 toxic effects is high (70.7%). In recent years, significant progress has been achieved in the systemic treatment of cholangiocarcinoma with immune checkpoint inhibitors (ICIs), targeted therapy, and hepatic artery infusion chemotherapy (HAIC).
View Article and Find Full Text PDFSurufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial.
Signal Transduct Target Ther
September 2024
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Article Synopsis
- A clinical trial was conducted to evaluate a novel four-drug regimen (surufatinib, toripalimab, etoposide, and cisplatin) for first-line treatment of advanced small cell lung cancer (SCLC), registered as NCT04996771.
- The primary measure of success was progression-free survival (PFS), while secondary measures included overall survival (OS) and response rates; results showed a 97.1% objective response rate and a median OS of 21.1 months.
- Although the treatment had a 63.2% rate of grade ≥3 adverse events, the adverse effects were manageable, suggesting that this regimen has promising efficacy with tolerable safety levels.
Case report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab.
Front Oncol
July 2024
Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Article Synopsis
- Undifferentiated small round-cell sarcomas (uSRCSs) are a tricky type of cancer to diagnose and treat, with no specific treatments available for advanced cases.
- A 37-year-old woman with advanced uSRCS tried several treatments that didn't work, including chemotherapy and a combination of other drugs.
- Finally, she responded well to a new treatment combining surufatinib and camrelizumab after many earlier treatments failed.
Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma.
Diagn Interv Radiol
June 2024
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- This study examines the clinical outcomes of 28 patients with advanced intrahepatic cholangiocarcinoma (ICC) who underwent a combination therapy involving hepatic arterial infusion chemotherapy, toripalimab, and surufatinib.
- Patients experienced an objective response rate of 58% and a disease control rate of 79%, with a median progression-free survival (mPFS) of 9.5 months and an overall survival rate of 83.3%.
- The treatment was generally safe, with nausea and vomiting being the most common side effects, but no serious complications leading to death were reported, indicating a promising avenue for future ICC treatment strategies.
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Cancer Immunol Immunother
May 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Article Synopsis
- A phase I study in China assessed the combination of toripalimab, a programmed death 1 inhibitor, and surufatinib, an angio-immuno kinase inhibitor, for patients with advanced solid tumors that had not responded to standard treatments.
- The study involved 60 patients across three cohorts (gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and biliary tract carcinoma), reporting objective response rates of 31.6%, 30.0%, and 11.1%, respectively.
- Preliminary results suggest that this combination therapy has promising anti-tumor effects and an acceptable safety profile, indicating the need for further research in larger clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!